Literature DB >> 25632199

Colectomy is a risk factor for venous thromboembolism in ulcerative colitis.

Gilaad G Kaplan1, Allen Lim1, Cynthia H Seow1, Gordon W Moran1, Subrata Ghosh1, Yvette Leung1, Jennifer Debruyn1, Geoffrey C Nguyen1, James Hubbard1, Remo Panaccione1.   

Abstract

AIM: To compare venous thromboembolism (VTE) in hospitalized ulcerative colitis (UC) patients who respond to medical management to patients requiring colectomy.
METHODS: Population-based surveillance from 1997 to 2009 was used to identify all adults admitted to hospital for a flare of UC and those patients who underwent colectomy. All medical charts were reviewed to confirm the diagnosis and extract clinically relevant information. UC patients were stratified by: (1) responsive to inpatient medical therapy (n=382); (2) medically refractory requiring emergent colectomy (n=309); and (3) elective colectomy (n=329). The primary outcome was the development of VTE during hospitalization or within 6 mo of discharge. Heparin prophylaxis to prevent VTE was assessed. Logistic regression analysis determined the effect of disease course (i.e., responsive to medical therapy, medically refractory, and elective colectomy) on VTE after adjusting for confounders including age, sex, smoking, disease activity, comorbidities, extent of disease, and IBD medications (i.e., corticosteroids, mesalamine, azathioprine, and infliximab). Point estimates were presented as odds ratios (OR) with 95%CI.
RESULTS: The prevalence of VTE among patients with UC who responded to medical therapy was 1.3% and only 16% of these patients received heparin prophylaxis. In contrast, VTE was higher among patients who underwent an emergent (8.7%) and elective (4.9%) colectomy, despite greater than 90% of patients receiving postoperative heparin prophylaxis. The most common site of VTE was intra-abdominal (45.8%) followed by lower extremity (19.6%). VTE was diagnosed after discharge from hospital in 16.7% of cases. Elective (adjusted OR=3.69; 95%CI: 1.30-10.44) and emergent colectomy (adjusted OR=5.28; 95%CI: 1.93-14.45) were significant risk factors for VTE as compared to medically responsive UC patients. Furthermore, the odds of a VTE significantly increased across time (adjusted OR=1.10; 95%CI: 1.01-1.20). Age, sex, comorbidities, disease extent, disease activity, smoking, corticosteroids, mesalamine, azathioprine, and infliximab were not independently associated with the development of VTE.
CONCLUSION: VTE was associated with colectomy, particularly, among UC patients who failed medical management. VTE prophylaxis may not be sufficient to prevent VTE in patients undergoing colectomy.

Entities:  

Keywords:  Deep vein thrombosis; Inflammatory bowel diseases; Pulmonary embolism; Surgery; Ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 25632199      PMCID: PMC4306170          DOI: 10.3748/wjg.v21.i4.1251

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

1.  Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.

Authors:  R S McLeod; W H Geerts; K W Sniderman; C Greenwood; R C Gregoire; B M Taylor; R E Silverman; K G Atkinson; M Burnstein; J C Marshall; C J Burul; D R Anderson; T Ross; S R Wilson; P Barton
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.

Authors:  Nilesh Chande; John Wd McDonald; John K Macdonald; Josh J Wang
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

3.  Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2004-07       Impact factor: 10.864

4.  Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study.

Authors:  A Gustavsson; G Järnerot; E Hertervig; I Friis-Liby; L Blomquist; P Karlén; C Grännö; M Vilien; M Ström; H Verbaan; P M Hellström; A Magnuson; J Halfvarson; C Tysk
Journal:  Aliment Pharmacol Ther       Date:  2010-08-18       Impact factor: 8.171

5.  Vascular complications of inflammatory bowel disease.

Authors:  R W Talbot; J Heppell; R R Dozois; R W Beart
Journal:  Mayo Clin Proc       Date:  1986-02       Impact factor: 7.616

6.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

7.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

8.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Craig A Solem; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

9.  Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.

Authors:  Susan R Kahn; Akbar Panju; William Geerts; Graham F Pineo; Louis Desjardins; Alexander G G Turpie; Stanislav Glezer; Lehana Thabane; Rolf J Sebaldt
Journal:  Thromb Res       Date:  2006-03-03       Impact factor: 3.944

10.  Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

Authors:  W Miehsler; W Reinisch; E Valic; W Osterode; W Tillinger; T Feichtenschlager; J Grisar; K Machold; S Scholz; H Vogelsang; G Novacek
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

View more
  7 in total

1.  Emergency colectomy for acute severe ulcerative colitis: a nationwide survey on technical strategies of the Italian society of colorectal surgery (SICCR).

Authors:  Michela Mineccia; Serena Perotti; Gianluca Pellino; Gianluca Matteo Sampietro; Valerio Celentano; Rodolfo Rocca; Marco Daperno; Alessandro Ferrero
Journal:  Updates Surg       Date:  2022-07-28

Review 2.  Preoperative optimization of patients with inflammatory bowel disease undergoing gastrointestinal surgery: a systematic review.

Authors:  Marie Strøm Zangenberg; Nir Horesh; Uri Kopylov; Alaa El-Hussuna
Journal:  Int J Colorectal Dis       Date:  2017-10-19       Impact factor: 2.571

Review 3.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Kimberly Cheng; Adam S Faye
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

4.  Inflammatory Bowel Disease and Thrombosis: A National Inpatient Sample Study.

Authors:  Jessica B Cohen; Diane M Comer; Jonathan G Yabes; Margaret V Ragni
Journal:  TH Open       Date:  2020-05-18

5.  Venous thromboembolism prophylaxis in inflammatory bowel disease flare-ups.

Authors:  Osama Kaddourah; Laith Numan; Sravan Jeepalyam; Omar Abughanimeh; Mouhanna Abu Ghanimeh; Khalil Abuamr
Journal:  Ann Gastroenterol       Date:  2019-08-31

6.  Epidemiology and Risk Factors of Portal Venous System Thrombosis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Hanyang Lin; Zhaohui Bai; Fanjun Meng; Yanyan Wu; Li Luo; Akash Shukla; Eric M Yoshida; Xiaozhong Guo; Xingshun Qi
Journal:  Front Med (Lausanne)       Date:  2022-01-17

7.  Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study.

Authors:  M Ellen Kuenzig; Alain Bitton; Matthew W Carroll; Gilaad G Kaplan; Anthony R Otley; Harminder Singh; Geoffrey C Nguyen; Anne M Griffiths; Therese A Stukel; Laura E Targownik; Jennifer L Jones; Sanjay K Murthy; Jeffrey D McCurdy; Charles N Bernstein; Lisa M Lix; Juan Nicolás Peña-Sánchez; David R Mack; Kevan Jacobson; Wael El-Matary; Trevor J B Dummer; Stephen G Fung; Sarah Spruin; Zoann Nugent; Divine Tanyingoh; Yunsong Cui; Christopher Filliter; Stephanie Coward; Shabnaz Siddiq; Eric I Benchimol
Journal:  J Crohns Colitis       Date:  2021-12-18       Impact factor: 9.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.